Spots Global Cancer Trial Database for Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Official Title: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy
Study ID: NCT00048581
Conditions
Study Description
Brief Summary: The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution, Birmingham, Alabama, United States
Local Institution, Mobile, Alabama, United States
Local Institution, Paradise Valley, Arizona, United States
Local Institution, La Jolla, California, United States
Local Institution, Long Beach, California, United States
Local Institution, Palo Alto, California, United States
Local Institution, Rancho Mirage, California, United States
Local Institution, Denver, Colorado, United States
Local Institution, Englewood, Colorado, United States
Local Institution, Bridgeport, Connecticut, United States
Local Institution, Hamden, Connecticut, United States
Local Institution, Clearwater, Florida, United States
Local Institution, Fort Lauderdale, Florida, United States
Local Institution, Largo, Florida, United States
Local Institution, Palm Harbor, Florida, United States
Local Institution, Tampa, Florida, United States
Local Institution, Rome, Georgia, United States
Local Institution, Indianapolis, Indiana, United States
Local Institution, Wichita, Kansas, United States
Local Institution, New Orleans, Louisiana, United States
Local Institution, Boston, Massachusetts, United States
Local Institution, Springfield, Massachusetts, United States
Local Institution, Lincoln, Nebraska, United States
Local Institution, New Brunswick, New Jersey, United States
Local Institution, Albany, New York, United States
Local Institution, Syracuse, New York, United States
Local Institution, Charlotte, North Carolina, United States
Local Institution, Hickory, North Carolina, United States
Local Institution, Bismarck, North Dakota, United States
Local Institution, Cincinnati, Ohio, United States
Local Institution, Oklahoma City, Oklahoma, United States
Local Institution, Eugene, Oregon, United States
Local Institution, Portland, Oregon, United States
Local Institution, Duncansville, Pennsylvania, United States
Local Institution, Norristown, Pennsylvania, United States
Local Institution, Sellersville, Pennsylvania, United States
Local Institution, Willow Grove, Pennsylvania, United States
Local Institution, Charleston, South Carolina, United States
Local Institution, Austin, Texas, United States
Local Institution, Dallas, Texas, United States
Local Institution, Vancouver, Washington, United States
Local Institution, Milwaukee, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
